Skyhawk Therapeutics Reveals Promising Findings for SKY-0515 in Huntington's Disease Clinical Trial

Skyhawk Therapeutics Unveils Interim Data from SKY-0515 Trial

On June 1, 2026, Skyhawk Therapeutics, Inc., a pioneer in clinical-stage biotechnology, revealed promising twelve-month interim results from its Phase 1/2 clinical trial assessing SKY-0515, a novel treatment targeted at Huntington's disease (HD). This breakthrough stems from a trial designed to gauge the efficacy and safety of SKY-0515 for patients suffering from this devastating neurodegenerative disorder.

The twelve-month findings reported a notable enhancement in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores, with a mean improvement of +0.38 from the baseline. This is in stark contrast to the anticipated decline of -0.92 points that was observed in symptomatic patients based on propensity score-weighted natural history analyses. These results indicate that SKY-0515 may offer a significant therapeutic advantage to those with HD, a disease which afflicts over 40,000 symptomatic individuals in the United States alone.

Moreover, SKY-0515 demonstrated a dose-dependent decrease in the mutant huntingtin protein (mHTT), a critical protein linked to HD pathology, achieving reductions of up to 69% after twelve months at a 9 mg dosage. These findings not only reflect the drug's potential to modify disease progression but also its ability to lower another protein, PMS1 mRNA, by up to 26%.

Phillip Sharp, PhD, a Nobel Prize laureate and founding member of Skyhawk's Scientific Advisory Board, emphasized the significance of these findings, stating that they showcase the extraordinary potential of using small molecules to modulate RNA splicing. The ongoing progress in this area indicates that Skyhawk may be setting the foundation for therapies that could transform the treatment landscape for numerous neurological disorders.

Bill Haney, co-founder and CEO of Skyhawk, shared his excitement regarding the data, highlighting the widening gap between the clinical trajectories of treated patients and natural history expectations. He expressed optimism about the sustained benefits observed in patients taking SKY-0515, which could potentially lead to a transformative oral treatment for Huntington's disease.

The SKY-0515 clinical studies have attracted considerable interest, with enrollment in the pivotal FALCON-HD study in Australia and New Zealand completing six months ahead of schedule with 144 participants, signaling robust engagement from the medical community and patients alike. The global Phase 2/3 FALCON-HD pivotal study has not only expanded its reach to eight countries but has also currently enrolled over 175 patients across various trial arms.

The study results represent a significant stride toward potentially providing the Huntington's community with much-needed therapeutic options. As noted by Ed Wild, a professor of neurology at University College London, the encouragement stemming from the positive safety and efficacy data strengthens the hypothesis that SKY-0515 could indeed bring meaningful change to the lives of those battling Huntington's disease.

Skyhawk’s proprietary SKYSTAR® platform is driving the development of SKY-0515, which aims to address the underlying causes of Huntington's disease at a molecular level. The company is committed to further advancing innovative therapies targeting rare neurological diseases, emphasizing its determination to offer patients accessible, impactful treatments by 2027.

As the research continues, the hope for improved outcomes for Huntington's disease patients grows stronger. SKY-0515 could potentially set the stage for a new era of treatment, making a tangible difference in the quality of life for affected individuals worldwide.